Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01090102 · ClinicalTrials.gov registry record · Phase 4
Mesalamine to Reduce T Cell Activation in HIV Infection
A Phase 4 study of HIV Infections and Sexually Transmitted Diseases, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 33
- Enrollment target
- 1
- Study location
NCT01090102: Completed Phase 4 study of HIV Infections and Sexually Transmitted Diseases, sponsored by University of California, San Francisco.
NCT01090102 is a Phase 4 study of HIV Infections and Sexually Transmitted Diseases that has completed, run by University of California, San Francisco. The registered enrollment target is 33 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01090102, a Phase 4 study of HIV Infections and Sexually Transmitted Diseases, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 33 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected patients, possibly resulting in better recovery of the immune system. The study hypothesis is that decreasing inflammation directly in the gut may decrease both of these potential causes of chronic inflammation, potentially resulting in an immunologic benefit.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Mesalamine (5-aminosalicylic acid, Apriso)
Study Locations (1)
California
- University of California, San Francisco-San Francisco General Hospital - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 33 participants |
| Start Date | 2010-06 |
| Est. Completion | 2012-12 |
| Phase | Phase 4 |
What the finished NCT01090102 record still lists
NCT01090102 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 33 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower).
The record links to 5 conditions, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01090102 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01090102 about?
NCT01090102 is a clinical study titled "Mesalamine to Reduce T Cell Activation in HIV Infection". The objective of this study is to determine whether 12 weeks of mesalamine therapy added to a standard HIV treatment decreases systemic immune activation and inflammation in HIV-infected patients, possibly resulting in better recovery of the immune system. The study hypothesis is that decreasing inf...
What is the current status of trial NCT01090102?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 33 participants. The study started on 2010-06. Estimated completion is 2012-12.
What conditions does trial NCT01090102 study?
This clinical trial studies the following conditions: HIV Infections, Sexually Transmitted Diseases, Immune System Diseases, Acquired Immunodeficiency Syndrome, Lentivirus Infections.
What interventions are being tested in trial NCT01090102?
The interventions under investigation include: Placebo (DRUG), Mesalamine (5-aminosalicylic acid, Apriso) (DRUG).
Who is sponsoring clinical trial NCT01090102?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01090102 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01090102's enrollment target sits among peer trials
33 417th of 542 higher than 123 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Accelerated ART Initiation for PWHIV Who Are Out of Care
RECRUITING · Phase 4
-
Vaccine Immunity and Inflammation in the Aging Person Living With HIV
RECRUITING · Phase 4
-
PrEP Intervention for People Who Inject Substances and Use Methamphetamine
RECRUITING · Phase 4
-
Boosted Atazanavir and Truvada Given Once-Daily - BATON Study
COMPLETED · Phase 4
-
"The Once A Day Protease Inhibitor Regimens"
COMPLETED · Phase 4
-
Buprenorphine and Integrated HIV Care
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02861898 · 33 participants · Phase 1
Super-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma
- NCT04871607 · 33 participants · Phase 2
Yttrium-90 Labeled Anti-CD25 Monoclonal Antibody Combined With BEAM Chemotherapy Conditioning for the Treatment of Primary Refractory or Relapsed Hodgkin Lymphoma
- NCT05071937 · 33 participants · Phase 2
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
- NCT05168618 · 33 participants · Phase 2
Cabozantinib and Atezolizumab for the Treatment of Metastatic Castration-Resistant Prostate Cancer, The AtezoCab Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia